1 Aebi C, Nadal D, Kind C, Pfister R, Barazzone C, Hammer J. Konsensus Statement zur Prävention von Respiratory Syncytial-Virus (RSV)-Infektionen bei Neugeborenen und Säuglingen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis). Schw Ärzteztg 1999;80:2927–2934.
2 Aebi C, Barazzone C, Hammer J, Kind C, Nadal D, Pfister RE. Update zum Konsensus-Statement zur Prävention von Respiratory Syncytial-Virus (RSV)-Infektionen bei Säuglingen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis). Paediatrica. 2002;13:58–60.
3 Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540.
4 Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of Respiratory Syncytial Virus hospitalisations in children with haemodynamically significant congenital heart disease. Arch Dis Child. 2004;89:961–965.
5 Duppenthaler A, Gorgievski-Hrisoho M, Frey U, Aebi C. Two-year periodicity of Respiratory Syncytial Virus epidemics in Switzerland. Infection. 2003;31:75–80.
6 The IMPACT study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–537.
7 Groothuis JR. Safety and tolerance of palivizumab administration in a large northern hemisphere trial. Pediatr Infect Dis J. 2001;20:628–630.
8 Oh PI, Lanctot KL, Yooh A et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J. 2002;21:512–518.
9 Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J. 2000;19:1068–1071.
10 Law BJ, Langley JM, Allen U et al. The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation. Pediatr Infect Dis J. 2004;23:806–814.
11 Lacaze-Masmonteil T, Truffert P, Pinquier D et al. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis Child. 2004;89:562–567.
12 Henckel E, Luthander J, Berggren E et al. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J. 2004;23:27–31.
13 Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003;22:823–827.
14 Parnes C, Guillermin J, Habersang R et al. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484–489.
15 Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics. 2002;110: e53.
16 Mohan AK, Braun MM, Ellenberg S, Hedje J, Cote TR. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr Infect Dis J. 2004;23:342–345.
17 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. NICHD-NHLBI-ORD workshop. Am J Respir Crit Care Med. 2001;163:
1723–1729.
18 Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137:865–870.
19 Tulloh R, Marsh M, Blackburn M et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young. 2003;13:420–423.
20 Saez-Llorens X, Moreno MT, Ramilo O, Sanchez PJ, Top FH, Jr., Connor EM. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J. 2004;23:707–712.
21 C. Aebi, C. Barazzone, J. Günthardt, J. Hammer, C. Kind, D. Nadal, J.-P. Pfammatter, R.E. Pfister. Konsensus Statement zur Prävention von Respiratory Syncytial Virus (RSV)-Infektionen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis®). Paediatrica. 2004;15(6).
22 American Academy of Pediatrics Policy Statement: Updated guidance for Palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415–420.
23 Pignotti MS, Leo MC, Pugi A et al.; Consensus conference on the appropriateness of palivizumab prophylaxis in RSV disease. Pediatr Pulmonol. 2016;51:1088–1096.